Comparative Effectiveness of Mannitol Versus Hypertonic Saline in Patients With Traumatic Brain Injury: A CENTER-TBI Study
Journal of Neurotrauma · 2023
DOI: 10.1089/neu.2022.0465 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurotrauma, 2023. Verfasst von Ernest van Veen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care Adults, Erasmus MC-University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Brain Injuries, Traumatic, Intracranial Hypertension. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Increased intracranial pressure (ICP) is one of the most important modifiable and immediate threats to critically ill patients suffering from traumatic brain injury (TBI). Two hyperosmolar agents (HOAs), mannitol and hypertonic saline (HTS), are routinely used in clinical practice to treat increased ICP. We aimed to assess whether a preference for mannitol, HTS, or their combined use translated into differences in outcome. The Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) Study is a prospective multi-center cohort study. For this study, patients with TBI, admitted to the intensive care unit (ICU), treated with mannitol and/or HTS, and aged ≥16 years were included. Patients and centers were differentiated based on treatment preference with mannitol and/or HTS based on structured, data-driven criteria such as first administered HOA in the ICU. We assessed influence of center and patient characteristics in the choice of agent using adjusted multi-variate models. Further, we assessed the influence of HOA preference on outcome using adjusted ordinal and logistic regression models, and instrumental variable analyses. In total, 2056 patients were assessed. Of these, 502 (24%) patients received mannitol and/or HTS in the ICU. The first received HOA was HTS for 287 (57%) patients, mannitol for 149 (30%) patients, or both mannitol and HTS on the same day for 66 (13%) patients. Two unreactive pupils were more common in patients receiving both (13, 21%), compared with patients receiving HTS (40, 14%) or mannitol (22, 16%). Center, rather than patient characteristics, was independently associated with the preferred choice of HOA ( p -value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Intensive Care Adults, Erasmus MC-University Medical Center, Rotterdam, The Netherlands.
- Department of Public Health, Erasmus MC-University Medical Center, Rotterdam, The Netherlands.
- Department of Medical Ethics and Philosophy of Medicine, Erasmus MC-University Medical Center, Rotterdam, The Netherlands.
- School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
- San Gerardo Hospital, ASST-Monza, Italy.
- Department of Physiopathology and Transplantation, Milan University, Milan, Italy.
Zitieren
APA
van Veen, E., Nieboer, D., Kompanje, E. J. O., Citerio, G., Stocchetti, N., Gommers, D., Menon, D. K., Ercole, A., Maas, A. I. R., Lingsma, H. F., & van der Jagt, M. (2023). Comparative Effectiveness of Mannitol Versus Hypertonic Saline in Patients With Traumatic Brain Injury: A CENTER-TBI Study. Journal of Neurotrauma. https://doi.org/10.1089/neu.2022.0465
Vancouver
van Veen E, Nieboer D, Kompanje EJO, Citerio G, Stocchetti N, Gommers D, et al. Comparative Effectiveness of Mannitol Versus Hypertonic Saline in Patients With Traumatic Brain Injury: A CENTER-TBI Study. Journal of Neurotrauma. 2023. doi:10.1089/neu.2022.0465
BibTeX
@article{vanVeen2023,
author = {van Veen, Ernest and Nieboer, Daan and Kompanje, Erwin J O and Citerio, Giuseppe and Stocchetti, Nino and Gommers, Diederik and Menon, David K and Ercole, Ari and Maas, Andrew I R and Lingsma, Hester F and van der Jagt, Mathieu},
title = {Comparative Effectiveness of Mannitol Versus Hypertonic Saline in Patients With Traumatic Brain Injury: A CENTER-TBI Study},
journal = {Journal of Neurotrauma},
year = {2023},
doi = {10.1089/neu.2022.0465}
}
EUVIMED